Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03279237 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
A Phase 1 study of GastroEsophageal Cancer, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03279237: Completed Phase 1 study of GastroEsophageal Cancer, sponsored by Massachusetts General Hospital.
NCT03279237 is a Phase 1 study of GastroEsophageal Cancer that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03279237, a Phase 1 study of GastroEsophageal Cancer, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer. The interventions involved in this study are: -FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Paclitaxel * Carboplatin * Proton Beam Radiation Therapy
Primary Outcome
The number of participants that complete the assigned study intervention.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Paclitaxel
- DRUG Irinotecan
- DRUG 5-Fluorouracil
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
What the finished NCT03279237 record still lists
NCT03279237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.
NCT03279237 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03279237 about?
NCT03279237 is a clinical study titled "A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers". This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer. The interventions involved in this study are: -FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Pacl...
What is the current status of trial NCT03279237?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-10-24. Estimated completion is 2024-02-29.
What conditions does trial NCT03279237 study?
This clinical trial studies the following conditions: GastroEsophageal Cancer.
What interventions are being tested in trial NCT03279237?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT03279237?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03279237 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroEsophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03279237's enrollment target sits among peer trials
25 18th of 23 higher than 6 of 23 other GastroEsophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GastroEsophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
COMPLETED · Phase 1
-
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI